Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jongphil Kim

Showing results (41-50 of 124) with videos related to

Pageof 13
Sort By:
Journal of Surgical Oncology|April 27, 2011
Neoadjuvant GTX chemotherapy and IMRT-based chemoradiation for borderline resectable pancreatic cancerManish Patel, Sarah Hoffe, Mokenge Malafa, et al.
Journal of Hematology & Oncology|October 8, 2010
Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemiaJoseph Pidala, Jongphil Kim, Claudio Anasetti, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 10, 2015
Myeloablative intravenous pharmacokinetically targeted busulfan plus fludarabine as conditioning for allogeneic hematopoietic cell transplantation in patients with non-Hodgkin lymphomaErnesto Ayala, Javier Figueroa, Janelle Perkins, et al.
Leukemia Research|June 4, 2014
Genomic aberrations deletion 11q and deletion 17p independently predict for worse progression-free and overall survival after allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemiaJulio C Chavez, Mohamed A Kharfan-Dabaja, Jongphil Kim, et al.
Clinical Nuclear Medicine|January 29, 2013
Variance of SUVs for FDG-PET/CT is greater in clinical practice than under ideal study settingsVirendra Kumar, Kavindra Nath, Claudia G Berman, et al.
American Journal of Surgery|July 2, 2013
Comparison of breast magnetic resonance imaging clinical tumor size with pathologic tumor size in patients status post-neoadjuvant chemotherapyMindy Williams, Jennifer Eatrides, Jongphil Kim, et al.
Cancer|May 27, 2020
A multi-institutional phase 2 trial of regorafenib in refractory advanced biliary tract cancerRichard D Kim, Hanna K Sanoff, Andrew S Poklepovic, et al.
Blood|August 3, 2013
Human regulatory T cells against minor histocompatibility antigens: ex vivo expansion for prevention of graft-versus-host diseaseAnandharaman Veerapathran, Joseph Pidala, Francisca Beato, et al.
Bone Marrow Transplantation|May 14, 2020
Associations among depression, antidepressants, survival and quality of life in hematopoietic cell transplant recipientsAnna Barata, Brian D Gonzalez, Jun-Min Zhou, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|June 13, 2014
Differences in BRCA counseling and testing practices based on ordering provider typeDeborah Cragun, Lucia Camperlengo, Emily Robinson, et al.
Pageof 13

Showing results (41-50 of 124) with videos related to

Sort By:
Pageof 13
Journal of Surgical Oncology|April 27, 2011
Neoadjuvant GTX chemotherapy and IMRT-based chemoradiation for borderline resectable pancreatic cancerManish Patel, Sarah Hoffe, Mokenge Malafa, et al.
Journal of Hematology & Oncology|October 8, 2010
Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemiaJoseph Pidala, Jongphil Kim, Claudio Anasetti, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 10, 2015
Myeloablative intravenous pharmacokinetically targeted busulfan plus fludarabine as conditioning for allogeneic hematopoietic cell transplantation in patients with non-Hodgkin lymphomaErnesto Ayala, Javier Figueroa, Janelle Perkins, et al.
Leukemia Research|June 4, 2014
Genomic aberrations deletion 11q and deletion 17p independently predict for worse progression-free and overall survival after allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemiaJulio C Chavez, Mohamed A Kharfan-Dabaja, Jongphil Kim, et al.
Clinical Nuclear Medicine|January 29, 2013
Variance of SUVs for FDG-PET/CT is greater in clinical practice than under ideal study settingsVirendra Kumar, Kavindra Nath, Claudia G Berman, et al.
American Journal of Surgery|July 2, 2013
Comparison of breast magnetic resonance imaging clinical tumor size with pathologic tumor size in patients status post-neoadjuvant chemotherapyMindy Williams, Jennifer Eatrides, Jongphil Kim, et al.
Cancer|May 27, 2020
A multi-institutional phase 2 trial of regorafenib in refractory advanced biliary tract cancerRichard D Kim, Hanna K Sanoff, Andrew S Poklepovic, et al.
Blood|August 3, 2013
Human regulatory T cells against minor histocompatibility antigens: ex vivo expansion for prevention of graft-versus-host diseaseAnandharaman Veerapathran, Joseph Pidala, Francisca Beato, et al.
Bone Marrow Transplantation|May 14, 2020
Associations among depression, antidepressants, survival and quality of life in hematopoietic cell transplant recipientsAnna Barata, Brian D Gonzalez, Jun-Min Zhou, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|June 13, 2014
Differences in BRCA counseling and testing practices based on ordering provider typeDeborah Cragun, Lucia Camperlengo, Emily Robinson, et al.
Pageof 13